ten23 health has officially joined the Alliance for RTU, a consortium of leading packaging manufacturers and pharmaceutical service providers dedicated to advancing technical standards and knowledge-sharing for ready-to-use (RTU) containers in sterile manufacturing.

This strategic move aims to accelerate the development, standardization, and adoption of high-quality RTU solutions, ultimately enhancing operational efficiency and patient safety across the life sciences sector.

ten23 health: A strategic addition to the Alliance for RTU

Based in Basel and Visp (Valais), ten23 health is recognized as a human-centric and sustainable CDMO partner for pharmaceutical companies and biotech start-ups. The company brings extensive expertise in the development, sterile fill & finish, and testing of drug products using RTU container platforms.

Its involvement in the Alliance for RTU is poised to strengthen the consortium’s technical capabilities and broaden the scope of RTU applications beyond syringes to include vials and cartridges—areas where significant technical challenges and opportunities remain.

The Alliance for RTU: driving technical exchange and standardization

Formed in September 2024 by industry leaders Gerresheimer, SCHOTT Pharma, and Stevanato Group, the Alliance for RTU was established to address the growing market need for advanced aseptic filling technologies.

The alliance serves as a collaborative platform for pharmaceutical companies, CMOs, and CDMOs to exchange expertise and technical knowledge on high-quality, ready-to-fill sterile primary packaging.

The long-term goal is to transition the industry toward standardized, high-quality sterile packaging, thereby improving manufacturing efficiency, regulatory compliance, and patient outcomes.

Expanding the scope of RTU container platforms

While RTU containers are widely adopted for syringes, their application to vials and cartridges presents unique technical hurdles. ten23 health’s experience with a diverse range of customer projects positions the company to contribute valuable insights into overcoming these challenges.

By sharing best practices and supporting the development of robust RTU platforms, ten23 health aims to facilitate broader adoption and standardization, ultimately enhancing the quality and reliability of injectable drug products.

Commitment to patient safety and sustainability

ten23 health’s participation in the Alliance aligns with its mission to develop differentiated, stable, and safe injectable treatment options. The company’s approach combines cutting-edge scientific research with deep regulatory expertise, ensuring that innovations in RTU container technology translate to tangible benefits for patients.

As a certified B Corp, ten23 health is also committed to delivering its services in a fair and sustainable manner, with a focus on both human health and environmental stewardship.

About the Alliance founding members

• Gerresheimer is a global provider of drug containment solutions, drug delivery systems, and medical devices, with over 40 production sites worldwide.

• SCHOTT Pharma specializes in drug containment and delivery systems for injectable medicines, serving over 1,800 customers globally.

• Stevanato Group offers integrated solutions across the drug development lifecycle, with a focus on technical innovation and engineering excellence.

Looking ahead

The addition of ten23 health to the Alliance for RTU marks a significant step forward in the collaborative effort to advance RTU technologies for sterile manufacturing. By leveraging shared expertise and fostering industry-wide technical exchange, the Alliance is well-positioned to drive innovation, improve operational efficiency, and enhance patient safety in the life sciences sector.

For more information about the Alliance for RTU, visit www.alliance-for-rtu.com.